Saisheng Pharmaceutical: Announcement on the Subsidiary’s Obtaining the Renewal of the “Drug Production License”
Securities code: 300485 Securities abbreviation: Saisheng Pharmaceutical Announcement number: 2026-017
Beijing Saisheng Pharmaceutical Co., Ltd.
Announcement on the Subsidiary's Obtaining the Renewal of the "Drug Production License"
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete.
There are false records, misleading statements or material omissions.
Shenyang Junyuan Pharmaceutical Co., Ltd. (hereinafter referred to as "Junyuan Pharmaceutical"), a subsidiary of Beijing Saisheng Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company"), recently received a renewed "Drug Production License" from the Liaoning Provincial Food and Drug Administration. The renewed "Drug Production License" is valid until March 24, 2031. The relevant information is now announced as follows:
1. Basic information of "Drug Production License"
Company name: Shenyang Junyuan Pharmaceutical Co., Ltd.
License number: Liao20210198
Unified social credit code: 91210112MA0P430D6R
Category code: AhzBh
Residence (business place): Building 9, Shenyang Hunnan Biomedical Industrial Park, No. 603 Maizitun, Hunnan District, Shenyang City
Legal representative: Wang Xuefeng
Person in charge of the company: Wang Guang
Production person in charge: Liu Huifeng
Quality manager: Tian Yuelin
Valid until: March 24, 2031
Production address and production scope:
Building 9, Building 22, No. 603 Maizitun, Hunnan District, Shenyang City: Tablets, granules, hard capsules, pills (water pills), solutions (external use, hormone-containing), tinctures (external use, hormone-containing), liniments, suppositories, small-volume injections***
2. Impact on the company
The renewal of the "Drug Production License" is an approval matter for re-issuance after the expiration of the original license. It will help Junyuan Pharmaceutical continue to maintain stable production capacity, ensure Junyuan Pharmaceutical's normal production and operation, and will not have a significant impact on the company's performance. Investors are kindly requested to invest rationally and pay attention to investment risks.
Announcement is hereby made.
Board of Directors of Beijing Saisheng Pharmaceutical Co., Ltd.
April 8, 2026